Chris Mullins

Chris joined the group as a PhD student in 2022 as part of the Molecular Sciences for Medicine (MoSMed) CDT. He graduated from The University of Warwick with an MBio in Biochemistry with Industrial Placement, during which he spent 12-months at UCB in Slough developing novel engineered antibody formats.  He then spent 2 years in Oxford at Evox Therapeutics, specialising in the downstream purification of exosomes for rare disease indications. Outside the lab, Chris enjoys exploring new places and playing/umpiring hockey.